Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy

OZCAN, Muhammet; Dizdar, ÖMER; DINCER, Nazmiye; BALCI, Serdar; Guler, GÜLNUR; GOK, Bahri; PEKTAS, Gokhan; SEKER, Mehmet; AKSOY, SERCAN; Arslan, ÇAĞATAY; Yalcin, ŞUAYİB; BALBAY, Mevlana

doi:10.1016/j.urolonc.2012.06.014

Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy

OZCAN M. F., Dizdar O., DINCER N., BALCI S., Guler G., GOK B., ...Daha Fazla

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, cilt.31, sa.8, ss.1709-1715, 2013 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 31 Sayı: 8
Basım Tarihi: 2013
Doi Numarası: 10.1016/j.urolonc.2012.06.014
Dergi Adı: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1709-1715
Hacettepe Üniversitesi Adresli: Evet

Özet

Purpose: Excision repair cross-complementation group 1 enzyme (ERCC1) plays a key role in the removal of platinum induced DNA adducts and cisplatin resistance. Prognostic role of ERCC1 expression in the neoadjuvant setting in bladder cancer has not been reported before. We evaluated the prognostic role of ERCC1 expression in bladder cancer receiving platinum-based neoadjuvant chemotherapy.